| Charles Mcclave, MD | |
|
2900 12th Ave N, Suite 160w, Billings, MT 59101-7506 | |
| (406) 237-8500 | |
| (406) 237-8501 |
| Full Name | Charles Mcclave |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 50 Years |
| Location | 2900 12th Ave N, Billings, Montana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023059094 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 4217 (Montana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Vincent Healthcare | Billings, MT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cogent Healthcare Of Montana P C | 4486712833 | 62 |
News Archive
The compound thymoquinone (TQ) selectively kills prostate cancer cells at advanced stages, according to a new study published in Oncogene.
Dr. Dino Terzic got lucky the other day. In his seventh and final year as a neurosurgery resident at the University of Minnesota, the 32-year-old Bosnian got to operate on a rare type of brain aneurysm that required a special approach through the patient's forehead. As Terzic prepared to slice into the patient's scalp, he was asked if he'd ever seen this type of flaw in an artery, which occurs in just 2 to 3 percent of aneurysm cases. "On a video," Terzic replied with a chuckle. Terzic's hands-on experience shows why the nation's medical schools are beset by a nagging controversy over rules that limit the number of hours residents can work (Dan Browning, 10/8).
An Australian team of scientists has uncovered a quality control mechanism that must take place for our immune system to subsequently effectively destroy harmful viruses and bacteria.
AbbVie released preliminary results from an ongoing Phase I study with ABT-414, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody drug conjugate, in combination with temozolomide, which showed four objective responses, including one complete response, in patients with recurrent or unresectable glioblastoma multiforme.
A step towards understanding cell mutations that cause a variety of human diseases, particularly in children - including that which brings about premature aging and early death - has been taken by researchers at the Hebrew University of Jerusalem Silberman Institute of Life Sciences and the John Hopkins University School of Medicine.
› Verified 7 days ago
| Entity Name | Scl Health Montana |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083655997 PECOS PAC ID: 3476457714 Enrollment ID: O20031229000380 |
News Archive
The compound thymoquinone (TQ) selectively kills prostate cancer cells at advanced stages, according to a new study published in Oncogene.
Dr. Dino Terzic got lucky the other day. In his seventh and final year as a neurosurgery resident at the University of Minnesota, the 32-year-old Bosnian got to operate on a rare type of brain aneurysm that required a special approach through the patient's forehead. As Terzic prepared to slice into the patient's scalp, he was asked if he'd ever seen this type of flaw in an artery, which occurs in just 2 to 3 percent of aneurysm cases. "On a video," Terzic replied with a chuckle. Terzic's hands-on experience shows why the nation's medical schools are beset by a nagging controversy over rules that limit the number of hours residents can work (Dan Browning, 10/8).
An Australian team of scientists has uncovered a quality control mechanism that must take place for our immune system to subsequently effectively destroy harmful viruses and bacteria.
AbbVie released preliminary results from an ongoing Phase I study with ABT-414, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody drug conjugate, in combination with temozolomide, which showed four objective responses, including one complete response, in patients with recurrent or unresectable glioblastoma multiforme.
A step towards understanding cell mutations that cause a variety of human diseases, particularly in children - including that which brings about premature aging and early death - has been taken by researchers at the Hebrew University of Jerusalem Silberman Institute of Life Sciences and the John Hopkins University School of Medicine.
› Verified 7 days ago
| Entity Name | Cogent Healthcare Of Montana P C |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053569525 PECOS PAC ID: 4486712833 Enrollment ID: O20081029000254 |
News Archive
The compound thymoquinone (TQ) selectively kills prostate cancer cells at advanced stages, according to a new study published in Oncogene.
Dr. Dino Terzic got lucky the other day. In his seventh and final year as a neurosurgery resident at the University of Minnesota, the 32-year-old Bosnian got to operate on a rare type of brain aneurysm that required a special approach through the patient's forehead. As Terzic prepared to slice into the patient's scalp, he was asked if he'd ever seen this type of flaw in an artery, which occurs in just 2 to 3 percent of aneurysm cases. "On a video," Terzic replied with a chuckle. Terzic's hands-on experience shows why the nation's medical schools are beset by a nagging controversy over rules that limit the number of hours residents can work (Dan Browning, 10/8).
An Australian team of scientists has uncovered a quality control mechanism that must take place for our immune system to subsequently effectively destroy harmful viruses and bacteria.
AbbVie released preliminary results from an ongoing Phase I study with ABT-414, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody drug conjugate, in combination with temozolomide, which showed four objective responses, including one complete response, in patients with recurrent or unresectable glioblastoma multiforme.
A step towards understanding cell mutations that cause a variety of human diseases, particularly in children - including that which brings about premature aging and early death - has been taken by researchers at the Hebrew University of Jerusalem Silberman Institute of Life Sciences and the John Hopkins University School of Medicine.
› Verified 7 days ago
| Entity Name | Hospitalist Medicine Physicians Of Nebraska-tcg, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487133963 PECOS PAC ID: 7911333810 Enrollment ID: O20200213001396 |
News Archive
The compound thymoquinone (TQ) selectively kills prostate cancer cells at advanced stages, according to a new study published in Oncogene.
Dr. Dino Terzic got lucky the other day. In his seventh and final year as a neurosurgery resident at the University of Minnesota, the 32-year-old Bosnian got to operate on a rare type of brain aneurysm that required a special approach through the patient's forehead. As Terzic prepared to slice into the patient's scalp, he was asked if he'd ever seen this type of flaw in an artery, which occurs in just 2 to 3 percent of aneurysm cases. "On a video," Terzic replied with a chuckle. Terzic's hands-on experience shows why the nation's medical schools are beset by a nagging controversy over rules that limit the number of hours residents can work (Dan Browning, 10/8).
An Australian team of scientists has uncovered a quality control mechanism that must take place for our immune system to subsequently effectively destroy harmful viruses and bacteria.
AbbVie released preliminary results from an ongoing Phase I study with ABT-414, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody drug conjugate, in combination with temozolomide, which showed four objective responses, including one complete response, in patients with recurrent or unresectable glioblastoma multiforme.
A step towards understanding cell mutations that cause a variety of human diseases, particularly in children - including that which brings about premature aging and early death - has been taken by researchers at the Hebrew University of Jerusalem Silberman Institute of Life Sciences and the John Hopkins University School of Medicine.
› Verified 7 days ago
| Entity Name | Hospitalist Medicine Physicians Of Montana - Tcs Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902567183 PECOS PAC ID: 5597143982 Enrollment ID: O20220525001139 |
News Archive
The compound thymoquinone (TQ) selectively kills prostate cancer cells at advanced stages, according to a new study published in Oncogene.
Dr. Dino Terzic got lucky the other day. In his seventh and final year as a neurosurgery resident at the University of Minnesota, the 32-year-old Bosnian got to operate on a rare type of brain aneurysm that required a special approach through the patient's forehead. As Terzic prepared to slice into the patient's scalp, he was asked if he'd ever seen this type of flaw in an artery, which occurs in just 2 to 3 percent of aneurysm cases. "On a video," Terzic replied with a chuckle. Terzic's hands-on experience shows why the nation's medical schools are beset by a nagging controversy over rules that limit the number of hours residents can work (Dan Browning, 10/8).
An Australian team of scientists has uncovered a quality control mechanism that must take place for our immune system to subsequently effectively destroy harmful viruses and bacteria.
AbbVie released preliminary results from an ongoing Phase I study with ABT-414, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody drug conjugate, in combination with temozolomide, which showed four objective responses, including one complete response, in patients with recurrent or unresectable glioblastoma multiforme.
A step towards understanding cell mutations that cause a variety of human diseases, particularly in children - including that which brings about premature aging and early death - has been taken by researchers at the Hebrew University of Jerusalem Silberman Institute of Life Sciences and the John Hopkins University School of Medicine.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Charles Mcclave, MD 1233 N 30th St, Billings, MT 59101-0127 Ph: (406) 237-3850 | Charles Mcclave, MD 2900 12th Ave N, Suite 160w, Billings, MT 59101-7506 Ph: (406) 237-8500 |
News Archive
The compound thymoquinone (TQ) selectively kills prostate cancer cells at advanced stages, according to a new study published in Oncogene.
Dr. Dino Terzic got lucky the other day. In his seventh and final year as a neurosurgery resident at the University of Minnesota, the 32-year-old Bosnian got to operate on a rare type of brain aneurysm that required a special approach through the patient's forehead. As Terzic prepared to slice into the patient's scalp, he was asked if he'd ever seen this type of flaw in an artery, which occurs in just 2 to 3 percent of aneurysm cases. "On a video," Terzic replied with a chuckle. Terzic's hands-on experience shows why the nation's medical schools are beset by a nagging controversy over rules that limit the number of hours residents can work (Dan Browning, 10/8).
An Australian team of scientists has uncovered a quality control mechanism that must take place for our immune system to subsequently effectively destroy harmful viruses and bacteria.
AbbVie released preliminary results from an ongoing Phase I study with ABT-414, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody drug conjugate, in combination with temozolomide, which showed four objective responses, including one complete response, in patients with recurrent or unresectable glioblastoma multiforme.
A step towards understanding cell mutations that cause a variety of human diseases, particularly in children - including that which brings about premature aging and early death - has been taken by researchers at the Hebrew University of Jerusalem Silberman Institute of Life Sciences and the John Hopkins University School of Medicine.
› Verified 7 days ago
Charles Wittnam, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 2675 Central Ave, Billings, MT 59102 Phone: 406-238-2500 | |
Phillip Embury Griffin, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 2938 Rockrim Ln, Billings, MT 59102 Phone: 406-259-7582 | |
Megan B Littlefield, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 123 S 27th St, Billings, MT 59101 Phone: 406-247-3350 Fax: 406-247-3389 | |
Karen C. Klee, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 | |
Brock P. Whittenberger, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 | |
Dr. Benjamin Girton Plank, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 |